Active Biotech AB Year-end report January - December 2012

Thu Feb 14, 2013 2:31am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130214:nHUGcWBJ



Events for the full year 2012
Laquinimod 

*Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)
*Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva
*Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US 
*Positive Crohn's Phase II data presented at the UEGW conference 
*Teva expands the clinical development program to encompass new indications 

                                          
TASQ      

*EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study 
*overall survival data from Phase II study presented 
*biomarker data presented at the ESMO conference 
*Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer anda second
study into additional cancer forms 
*Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen        
   

           
ANYARA     

*Phase II/III study in renal cell cancer concluded
* -- -  Results presented during Q1, 2013: study did not achieve primary clinical endpoint 
doubling of progression free survival and OS in 25 % of patientsplanning of the continued clinical
development ongoing

57-57             

*clinical trial of systemic sclerosis/scleroderma concluded

ISI                 

*focus on patent submissions H1 2013
*project proceeds as planned

                                    Oct - Dec     Jan - Dec       
 (MSEK)                              2012   2011   2012    2011   
 *     Net sales                     91.5   3.3    227.9   234.6  
 *     Operating profit/loss         5.5   -94.7  -163.2  -100.9  
 *     Net profit/loss               0.1   -93.2  -175.0   -94.5  
 *     Profit/loss per share (SEK)   0.00  -1.35   -2.54   -1.38  


For further information, please contact:

Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95                                       
  
Hans Kolam, CFO Tel: +46 (0)46 19 20 44
                                                                                
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund 
Tel: +46 (0)46 19 20 00, Fax +46 (0)46 19 11 00
This report is also available at www.activebiotech.com http://www.activebiotech.com/ 



Active Biotech AB Year-end report Jan-Dec 2012 http://hugin.info/1002/R/1678129/547591.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE


HUG#1678129

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.